Journal of Clinical Oncology, Vol 15, 1465-1469, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial

AV D'Amico, R Whittington, SB Malkowicz, D Schultz, JE Tomaszewski and A Wein
Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA. ADAMICO@JCRT.harvard.edu

PURPOSE: A multivariable analysis to evaluate the potential clinical and pathologic factors that predict for early biochemical failure in patients with pathologically organ-confined and margin-negative disease was performed to define patients who may benefit from adjuvant therapy. PATIENTS AND METHODS: Three hundred forty-one prostate cancer patients treated with a radical retropubic prostatectomy between January 1989 and June 1995 and found to have pathologically organ-confined and margin-negative disease comprised the study population. A logistic regression multivariable analysis to evaluate the predictive value of the preoperative prostate-specific antigen (PSA) level, pathologic (prostatectomy) Gleason score, and pathologic stage on PSA failure occurring during the first postoperative year was performed. RESULTS: Predictors of PSA failure during the first postoperative year in patients with pathologically organ-confined disease included pathologic Gleason score > or = 7 (P = .0007) and preoperative PSA level greater than 10 (P < .0001). Corresponding 3-year freedom-from-PSA-failure rates for these pathologic organ-confined patients with both, one, or neither of these factors were 60%, 75% to 84%, and 95%, respectively (P < .0001). CONCLUSION: Prostate cancer patients with pathologically organ-confined and margin-negative disease and a preoperative PSA level greater than 10 ng/mL or a pathologic Gleason score > or = 7 have significant decrements in short-term PSA-failure-free survival. Therefore, these patients should be considered for adjuvant therapy in the setting of a phase III clinical trial.

This article has been cited by other articles:

				R E Emerson, M O Koch, T D Jones, J K Daggy, B E Juliar, and L Cheng The influence of extent of surgical margin positivity on prostate specific antigen recurrence J. Clin. Pathol., October 1, 2005; 58(10): 1028 - 1032. [Abstract] [Full Text] [PDF]

				Y.-C. Ou, J.-T. Chen, C.-R. Yang, C.-L. Cheng, H.-C. Ho, J.-L. Ko, and Y.-S. Hsieh Predicting Prostate Specific Antigen Failure after Radical Retropubic Prostatectomy for T1c Prostate Cancer Jpn. J. Clin. Oncol., December 1, 2002; 32(12): 536 - 542. [Abstract] [Full Text] [PDF]

				A. V. D'Amico Predicting Prostate-Specific Antigen Recurrence Established: Now, Who Will Survive? J. Clin. Oncol., August 1, 2002; 20(15): 3188 - 3190. [Full Text] [PDF]

				S. Gripp, J. C. Haller, J. Metz, and R. Willers Prostate-Specific Antigen: Effect of Pelvic Irradiation Radiology, June 1, 2000; 215(3): 757 - 760. [Abstract] [Full Text]

				A. V. D’Amico, R. Whittington, S. B. Malkowicz, D. Schultz, J. Fondurulia, M.-H. Chen, J. E. Tomaszewski, A. A. Renshaw, A. Wein, and J. P. Richie Clinical Utility of the Percentage of Positive Prostate Biopsies in Defining Biochemical Outcome After Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer J. Clin. Oncol., March 13, 2000; 18(6): 1164 - 1172. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, R. Whittington, S. B. Malkowicz, J. Fondurulia, M.-H. Chen, I. Kaplan, C. J. Beard, J. E. Tomaszewski, A. A. Renshaw, A. Wein, et al. Pretreatment Nomogram for Prostate-Specific Antigen Recurrence After Radical Prostatectomy or External-Beam Radiation Therapy for Clinically Localized Prostate Cancer J. Clin. Oncol., January 1, 1999; 17(1): 168 - 168. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, R. Whittington, S. B. Malkowicz, D. Schultz, K. Blank, G. A. Broderick, J. E. Tomaszewski, A. A. Renshaw, I. Kaplan, C. J. Beard, et al. Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer JAMA, September 16, 1998; 280(11): 969 - 974. [Abstract] [Full Text] [PDF]